牛牛AI助理已提取核心訊息
On February 28, 2024, Butterfly Network, Inc., a digital health company known for its innovative ultrasound technology, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported revenue of $65.9 million, exceeding expectations, and announced the launch of its next-generation device, the iQ3, and ScanLab in 2024. Butterfly Network successfully completed a cost reduction initiative, removing over $170 million in expenses and reducing its annual cash burn to approximately $60 million. The company also revealed plans for an Investor Day on March 18, 2024, at the New York Stock Exchange. Joseph DeVivo, Butterfly's Chairman and CEO, highlighted 2023 as a transition year, emphasizing the company's efforts in rightsizing the business and investing in growth channels. The early 2024 FDA clearance and launch...Show More
On February 28, 2024, Butterfly Network, Inc., a digital health company known for its innovative ultrasound technology, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported revenue of $65.9 million, exceeding expectations, and announced the launch of its next-generation device, the iQ3, and ScanLab in 2024. Butterfly Network successfully completed a cost reduction initiative, removing over $170 million in expenses and reducing its annual cash burn to approximately $60 million. The company also revealed plans for an Investor Day on March 18, 2024, at the New York Stock Exchange. Joseph DeVivo, Butterfly's Chairman and CEO, highlighted 2023 as a transition year, emphasizing the company's efforts in rightsizing the business and investing in growth channels. The early 2024 FDA clearance and launch of the Butterfly iQ3, featuring advanced semiconductor chip technology, positions the company for growth. Butterfly Network also announced partnerships and agreements, such as with Mendaera and Forest Neurotech, and the expansion of its Butterfly Garden ecosystem. The company completed a significant cost reduction and reorganization, aiming to extend its cash runway into 2026 and reinvest in its sales team. Despite a net loss of $44.1 million for the quarter, the company's adjusted EBITDA loss improved compared to the previous year. Butterfly Network ended the year with $138.7 million in cash, cash equivalents, and restricted cash, and provided guidance for low double-digit revenue growth and an adjusted EBITDA loss of $60 million to $50 million for fiscal year 2024.
2024年2月28日，以創新的超聲技術而聞名的數字健康公司Butterfly Network, Inc. 公佈了截至2023年12月31日的第四季度和全年財務業績。該公司公佈的收入爲6,590萬美元，超出預期，並宣佈將於2024年推出其下一代設備iQ3和ScanLab。Butterfly Network成功完成了一項成本削減計劃，減少了超過1.7億美元的支出，並將其每年的現金消耗減少到約6000萬美元。該公司還透露了2024年3月18日在紐約證券交易所舉辦投資者日的計劃。Butterfly董事長兼首席執行官約瑟夫·德維沃強調2023年是過渡年，強調了公司在調整業務規模和投資增長渠道方面所做的努...展開全部
2024年2月28日，以創新的超聲技術而聞名的數字健康公司Butterfly Network, Inc. 公佈了截至2023年12月31日的第四季度和全年財務業績。該公司公佈的收入爲6,590萬美元，超出預期，並宣佈將於2024年推出其下一代設備iQ3和ScanLab。Butterfly Network成功完成了一項成本削減計劃，減少了超過1.7億美元的支出，並將其每年的現金消耗減少到約6000萬美元。該公司還透露了2024年3月18日在紐約證券交易所舉辦投資者日的計劃。Butterfly董事長兼首席執行官約瑟夫·德維沃強調2023年是過渡年，強調了公司在調整業務規模和投資增長渠道方面所做的努力。採用先進半導體芯片技術的Butterfly iQ3於2024年初獲得美國食品藥品管理局的批准和推出，爲公司的增長奠定了基礎。Butterfly Network還宣佈了合作伙伴關係和協議，例如與Mendaera和Forest Neurotech的合作伙伴關係和協議，以及擴大其蝴蝶園生態系統。該公司完成了重大成本削減和重組，目標是將其現金流延長至2026年，並對銷售團隊進行再投資。儘管本季度淨虧損4,410萬美元，但該公司調整後的息稅折舊攤銷前利潤虧損與去年相比有所改善。Butterfly Network在年底擁有1.387億美元的現金、現金等價物和限制性現金，併爲2024財年的低兩位數收入增長和調整後的息稅折舊攤銷前利潤虧損6000萬至5000萬美元提供了指導。
有用
沒用